Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hemophilia A

• Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
• A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
• A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
• Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
• rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
• Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
• Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
• Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
• SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
• Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
• Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
• ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor
• A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
• An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody in Acquired Hemophilia A
• A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
• A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors
• The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
• Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
• Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
• A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
• A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
• A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
• Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
• Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
• Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
• A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
• Emicizumab in Patients With Acquired Hemophilia A
• A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
• Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
• Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A
• Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
• Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
• A Phase II, Muti-Center Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A
• A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection
• A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
• A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
• A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People
• Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
• A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
• Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
• A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
• A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
• Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
• Intensive Replacement Treatment in Haemophilia Patients With Synovitis
• Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
• Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
• A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
• Health Related Quality of Life of Youth and Young Adults With Haemophilia A
• POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
• Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV With Hemophilia.
• BT200 in Hereditary Bleeding Disorders
• SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
• Preventing Inhibitor Recurrence Indefinitely
• A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
• Hemlibra in Mild Hemophilia A
• SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
• An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
• Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
• The Hemophilia Inhibitor Eradication Trial
• The Hemophilia Inhibitor Prevention Trial
• A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
• A Research Study Investigating Mim8 in People With Haemophilia A
• Emicizumab in Acquired Hemophilia A
• A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
• The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients
• Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation)
• Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
• Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
• The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B)
• Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
• Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
• Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
• Emicizumab PUPs and Nuwiq ITI Study
• Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
• Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
• Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
• Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
• Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
• Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A
• Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
• Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
• Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
• Pharmacokinetic (PK)Research on Chinese Children of Hemophilia
• Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China
• Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
• Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
• Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altere
• Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVII
• A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
• A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
• Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
• Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
• Exercise Versus DDAVP in Patients With Mild Hemophilia A
• Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
• A Study of BAX 888 in Male Adults With Severe Hemophilia A
• BAY94-9027 PK Study Comparing to Another Long Acting Product
• Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
• Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
• Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
• INdividualized ITI Based on Fviii(ATE) Protection by VWF
• A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
• A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
• A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
• DDAVP vs. Exercise in Patients With Mild Hemophilia A
• A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
• Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
• Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
• The European Paediatric Network for Haemophilia Management ( PedNet Registry)
• Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
• Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
• Drug Use Investigation of Kovaltry in Hemophilia A Patients
• Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
• Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
• Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
• A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Sev
• A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
• A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
• Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients
• Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
• Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
• Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
• Weight-based Dosing in Hemophilia A
• Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
• A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
• An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
• Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
• PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
• Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
• Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
• Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
• Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
• A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
• Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
• A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
• Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
• Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
• Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China
• Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
• Prospective Biomarkers of Bone Metabolism in Hemophilia A
• Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
• Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
• An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B
• To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
• Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
• Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
• Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
• A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
• Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
• Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
• A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
• Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
• A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor
• Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A
• A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
• Viral Kinetics in HCV Clearance in Subjects With Hemophilia
• Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
• Hemophilia Inhibitor Previously Untreated Patient Study
• A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
• A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
• Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice
• Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
• Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
• Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers
• Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
• Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
• Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
• Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
• Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
• Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
• Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
• Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
• Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B
• Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients
• Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
• Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A
• Turkish Acquired Haemophilia Registry
• Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
• Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
• Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
• A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
• Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
• Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
• Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
• Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects
• Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
• A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
• Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
• Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
• Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
• Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
• First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
• Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
• Prophylaxis Versus On-demand Therapy Through Economic Report
• Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
• rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
• Survey of Inhibitors in Plasma-Product Exposed Toddlers
• Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive
• Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
• Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
• Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B
• Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
• Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
• Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
• Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
• A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
• Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
• Study of Ataluren (PTC124) in Hemophilia A and B
• Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
• Study Evaluating Pharmacovigilance Of Refacto AF
• Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
• PROPACT: Retrospective Prophylaxis Patient Case Collection
• International PMS Study - KOGENATE Bayer
• Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
• Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
• Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
• Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
• Phase I/IIa Study of FIXFc in Hemophilia B Patients
• Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
• Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
• Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
• Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
• Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A
• Clinical Trial of Factor XIII (FXIII) Concentrate
• Russian Kogenate Pediatric Study
• Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
• BAY14-2222 Continuous Infusion in Surgeries
• BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
• Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
• High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
• Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
• Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
• Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
• Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
• Rituximab to Treat Severe Hemophilia A
• Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
• Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
• Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
• Clot Formation and Clot Stability in Patients With Severe Haemophilia A
• Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.
• Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII
• Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients
• Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
• Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
• ADVATE Post Authorization Safety Surveillance
• International Immune Tolerance Study
• Study Evaluating Refacto For Pharmacovigilance
• Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
• Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
• Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
• The FEIBA NovoSeven Comparative Study
• Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients
• Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
• Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
• Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
• Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)
• Trial of NovoSeven® in Haemophilia - Joint Bleeds
• Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
• Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B
• Study Evaluating rFIX; BeneFIX® in Hemophilia B
• Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
• Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
• Study Evaluating ReFacto in Hemophilia A
• Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
• Study Evaluating ReFacto AF in Severe Hemophilia A
• Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
• The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
• Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia
• Cooperative Study of Factor VIII Inhibitors